Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension

NCT00811018 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00811018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2003
Completion date
July 31, 2011
Enrollment
1,192 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension